Zimmer Biomet Holdings, Inc.

ZBH Healthcare Medical Devices

Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024. In the quarter to June 2026, revenue grew 4.80%, EPS grew 33.8%, free cash flow grew 13.1% and total debt fell 1.23%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five.

95.06 0.68 +0.72%
Market cap
$18.0B
P/E
23.0×
Fwd P/E
17.7×
Dividend yield
1.01%
F-score
6/9
Altman Z
2.38
Beneish M
−2.59
Dividend safety
72/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
20.85 23.36 25.19 24.26

+8 more quarters

P/S ratio
1.94 2.10 2.16 2.44
P/FCF ratio
15.96 17.49 16.53 19.29
P/Operating CF
36.95 49.06 34.41 46.60
P/B ratio
1.31 1.39 1.40 1.53
EV/Sales
2.78 2.93 3.00 3.29
EV/EBITDA
10.21 10.78 11.28 10.94
EV/FCF
22.78 24.48 22.96 26.04
Current Ratio
1.69 1.73 1.98 2.43
Net Debt/EBITDA
11.84 10.96 15.80 10.74
Debt/Equity
0.59 0.59 0.59 0.64
Earnings Yield
4.80% 4.28% 3.97% 4.12%
Free Cash Flow Yield
6.26% 5.72% 6.05% 5.18%
Free Cash Flow per Share
1.28 1.06 1.60 1.35
Book value per Share
65.73 65.03 64.17 64.44
Free Cash Flow
246.00 206.90 315.90 267.70
EV/EBIT
19.60 20.93 22.52 19.76
Other line items

Show all line items

Columns are period end dates